Ustekinumab for Ichthyosis

Phase-Based Progress Estimates
Northwestern University/Lurie Children's Hospital, Chicago, ILIchthyosisUstekinumab - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will test whether the drug ustekinumab is safe and effective for treating people with ichthyosis, a group of lifelong genetic disorders characterized by generalized skin thickening, scaling, and underlying cutaneous inflammation.

Eligible Conditions
  • Ichthyosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 7 months after initiation of study drug

Month 7
Occurence of bacterial and fungal infections
Reduction in Ichthyosis Severity Score

Trial Safety

Safety Progress

1 of 3

Side Effects for

Ustekinumab (Stelara)
50%Upper respiratory infection
27%Common cold
9%Back pain
9%Urinary tract infection
9%Skin and subcutaneous tissue disorders
5%Pain/Pain in extremity
5%Rash/Rash Acneiform/Maculo-Papular
This histogram enumerates side effects from a completed 2018 Phase 4 trial (NCT02187172) in the Ustekinumab (Stelara) ARM group. Side effects include: Upper respiratory infection with 50%, Common cold with 27%, Back pain with 9%, Fracture with 9%, Anxiety with 9%.

Trial Design

1 Treatment Group

Open Label
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Ustekinumab · No Placebo Group · Phase < 1

Open Label
Experimental Group · 1 Intervention: Ustekinumab · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 7 months after initiation of study drug

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,476 Previous Clinical Trials
811,130 Total Patients Enrolled
5 Trials studying Ichthyosis
1,198 Patients Enrolled for Ichthyosis
Janssen Scientific Affairs, LLCIndustry Sponsor
144 Previous Clinical Trials
578,118 Total Patients Enrolled
Amy Paller, MDPrincipal Investigator - Northwestern University
Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Memorial Hospital
Stanford University School Of Medicine (Medical School)
Northwestern Mem Hospital (Residency)
17 Previous Clinical Trials
2,727 Total Patients Enrolled
2 Trials studying Ichthyosis
963 Patients Enrolled for Ichthyosis

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What clinical indications is Ustekinumab commonly prescribed for?

"Ustekinumab is generally used to regulate the production of adrenal cortex hormones. It may additionally be prescribed as a last resort for conditions such as psoriasis, an inadequate response to one or more tnf antagonist therapies, and severe active Crohn's Disease." - Anonymous Online Contributor

Unverified Answer

Can you elaborate on any other research trials that have utilized Ustekinumab?

"Currently, 34 trials involving Ustekinumab are ongoing with 17 of those in the final stage. While Warsaw, Mazowieckie is one of the locations for these tests, 2820 other medical sites worldwide are also running studies about this drug." - Anonymous Online Contributor

Unverified Answer

What is the upper limit of participants enrolled in this medical research?

"That is correct. reveals that this research trial, which was initiated on April 1st 2021, requires 15 participants and is currently looking for volunteers from one location." - Anonymous Online Contributor

Unverified Answer

Are there any openings to join this clinical experiment?

"Indeed, according to the information on this trial is currently enrolling patients. The initial posting was made April 1st 2021 and has been edited as recently as April 19th 2022. 15 individuals are being sought from a single site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.